Table 7.
Comparison of the diagnostic utility of single CA15-3 and CEA assays and selected combinations of these markers with miRNAs in diagnosis of BC patients
| Parameter | SN [%] | SP [%] | AUC | References |
|---|---|---|---|---|
| (healthy controls vs BC) | Zaleski et al. (2018) | |||
| CEA | 26.0/18.0 | 90.0/95.0 | 0.717 | |
| CA15-3 | 36.2/31.9 | 90.0/95.0 | 0.721 | |
| miR-34a+CEA | 59.1/34.1 | 90.0/95.0 | 0.844 | |
| miR-34a+CA15-3 | 56.1/56.1 | 90.0/95.0 | 0.800 | |
| (benign breast diseases vs BC) | ||||
| CEA | 20.0/20.0 | 90.0/95.0 | 0.623 | |
| CA15-3 | 25.5/23.4 | 90.0/95.0 | 0.619 | |
| miR34a+CEA | 54.5/31.8 | 90.0/95.0 | 0.794 | |
| miR34a+CA15-3 | 53.7/53.7 | 90.0/95.0 | 0.741 | |
| CA15-3 | 80 | 73.3 | 0.829 | Raheem et al. (2019) |
| miRNA-34a+CA15-3 | 83.3 | 77.7 | 0.842 | |
| CEA | 32 | 100 | 0.615 | Qiao et al. (2024) |
| CA15-3 | 53.19 | 91.49 | 0.727 | |
| miR-200c+CEA+CA15-3+CA125 | 91.49 | 76.6 | 0.9140 | |